These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2788499)

  • 1. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I; Agah R; Hu E; Mazumder A
    Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
    Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
    Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
    Berinstein N; Levy R
    J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
    Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate.
    LeBerthon B; Khawli LA; Alauddin M; Miller GK; Charak BS; Mazumder A; Epstein AL
    Cancer Res; 1991 May; 51(10):2694-8. PubMed ID: 2021947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
    Munn DH; Cheung NK
    Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
    Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
    Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
    Epstein AL; Khawli LA; Hornick JL; Taylor CR
    Cancer Res; 1995 Jun; 55(12):2673-80. PubMed ID: 7780984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake.
    Hu P; Hornick JL; Glasky MS; Yun A; Milkie MN; Khawli LA; Anderson PM; Epstein AL
    Cancer Res; 1996 Nov; 56(21):4998-5004. PubMed ID: 8895756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
    Zhang WX; Guo J; Lin BH; Meng SN; Wang XP; Xie Y; Zheng W; Zhang YT; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):41-4. PubMed ID: 17649726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.